Literature DB >> 28619632

Enhancing prostate cancer survivorship care through self-management.

Ted A Skolarus1, Daniela Wittmann2, Sarah T Hawley3.   

Abstract

The lack of clear roles for prostate cancer survivorship care providers places prostate cancer survivors at significant risk of inappropriate use of services delivered piecemeal by different providers, persistent bothersome symptoms, and silent suffering. Optimizing quality of care for prostate cancer survivors hinges on decreasing fragmentation of care, and providing quality symptom management. This is achieved through comprehensive, appropriate medical, surgical, pharmacological and psychosocial care, coupled with self-management, as highlighted in several recent resources addressing long-term and late effects of treatment. Although further study is warranted, prostate cancer survivors engaging in self-management may reduce the negative impact of prostate cancer in their lives through better quality of care (better symptom management and efficient use of services) and quality of life. Published by Elsevier Inc.

Entities:  

Keywords:  Coping; Implementation; Information needs; Prostate cancer; Satisfaction; Survivorship; Symptoms; Tailoring

Mesh:

Year:  2017        PMID: 28619632     DOI: 10.1016/j.urolonc.2017.05.008

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  2 in total

1.  Randomised controlled trial to investigate the effectiveness of the symptom management after radiotherapy (SMaRT) group intervention to ameliorate lower urinary tract symptoms in men treated for prostate cancer.

Authors:  Sara Faithfull; Jane Cockle-Hearne; Agnieszka Lemanska; Sophie Otter; Simon S Skene
Journal:  Support Care Cancer       Date:  2021-12-21       Impact factor: 3.359

2.  Prostate cancer survivorship essentials framework: guidelines for practitioners.

Authors:  Jeff Dunn; Anna Green; Nicholas Ralph; Robert U Newton; Andrew Kneebone; Mark Frydenberg; Suzanne K Chambers
Journal:  BJU Int       Date:  2020-08-18       Impact factor: 5.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.